LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 4 of total 4

Search options

  1. Article: Combination of Extended Antivirals With Antiretrovirals for Severe Mpox in Advanced Human Immunodeficiency Virus Infection: Case Series of 4 Patients.

    Duong, Michael T / Tebas, Pablo / Ancha, Bhavya / Baron, Jillian / Chary, Pallavi / Isaacs, Stuart N / Szep, Zsofia

    Open forum infectious diseases

    2024  Volume 11, Issue 3, Page(s) ofae110

    Abstract: To gauge the safety and utility of extended tecovirimat/cidofovir for severe mpox, here we report our experience caring for 4 patients with mpox and advanced human immunodeficiency virus (HIV) at the Hospitals of the University of Pennsylvania during the ...

    Abstract To gauge the safety and utility of extended tecovirimat/cidofovir for severe mpox, here we report our experience caring for 4 patients with mpox and advanced human immunodeficiency virus (HIV) at the Hospitals of the University of Pennsylvania during the 2022 global outbreak. Three patients had recurrent courses complicated by superinfections, coinfections and insufficient nutrition/housing, requiring extended tecovirimat (5-16 weeks) and cidofovir (1-12 doses) with probenecid and fluids. At follow-up, patients had undetectable HIV RNA on antiretrovirals, improved ulcers and stable renal function on antivirals. Serology guided cessation for one 7-month cidofovir course. Overall findings support a comprehensive approach of prolonged tecovirimat/cidofovir with antiretrovirals for severe mpox, while addressing social factors.
    Language English
    Publishing date 2024-02-27
    Publishing country United States
    Document type Case Reports
    ZDB-ID 2757767-3
    ISSN 2328-8957
    ISSN 2328-8957
    DOI 10.1093/ofid/ofae110
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  2. Article: Case Series of People With HIV on the Long-Acting Combination of Lenacapavir and Cabotegravir: Call for a Trial.

    Gandhi, Monica / Hill, Lucas / Grochowski, Janet / Nelson, Alexander / Koss, Catherine A / Mayorga-Munoz, Francis / Oskarsson, Jon / Shiels, Mary / Avery, Ann / Bamford, Laura / Baron, Jillian / Short, William R / Hileman, Corrilynn O

    Open forum infectious diseases

    2024  Volume 11, Issue 4, Page(s) ofae125

    Abstract: Background: Injectable cabotegravir (CAB)/rilpivirine (RPV) is the only combination long-acting (LA) antiretroviral regimen approved for HIV. RPV may not be effective among individuals with non-nucleoside reverse transcriptase inhibitor (NNRTI) ... ...

    Abstract Background: Injectable cabotegravir (CAB)/rilpivirine (RPV) is the only combination long-acting (LA) antiretroviral regimen approved for HIV. RPV may not be effective among individuals with non-nucleoside reverse transcriptase inhibitor (NNRTI) resistance, which has >10% prevalence in many countries. Lenacapavir (LEN) is an LA capsid inhibitor given every 6 months, but has not been studied in combination with other LA agents.
    Methods: We assembled a case series from 4 US academic medical centers where patients with adherence challenges were prescribed LEN subcutaneously every 26 weeks/CAB (+/- RPV) intramuscularly every 4 or 8 weeks. Descriptive statistics, including viral load (VL) outcomes, were summarized.
    Results: All patients (n = 34: 76% male; 24% cis/trans female; 41% Black; 38% Latino/a; median age [range], 47 [28-75] years; 29% and 71% on CAB every 4 or 8 weeks) reported challenges adhering to oral ART. The reasons for using LEN/CAB with or without RPV were documented or suspected NNRTI mutations (n = 21, 59%), integrase mutations (n = 5, 15%), high VL (n = 6, 18%), or continued viremia on CAB/RPV alone (n = 4, 12%). Injection site reactions on LA LEN were reported in 44% (32% grade I, 12% grade 2). All patients but 2 (32/34; 94%) were suppressed (VL <75 copies/mL) after starting LEN at a median (range) of 8 (4-16) weeks, with 16/34 (47%) suppressed at baseline.
    Conclusions: In this case series of 34 patients on LEN/CAB, high rates of virologic suppression (94%) were observed. Reasons for using LEN/CAB included adherence challenges and underlying resistance, mostly to NNRTIs. These data support a clinical trial of LEN/CAB among persons with NNRTI resistance.
    Language English
    Publishing date 2024-04-16
    Publishing country United States
    Document type Journal Article
    ZDB-ID 2757767-3
    ISSN 2328-8957
    ISSN 2328-8957
    DOI 10.1093/ofid/ofae125
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  3. Article ; Online: Clinical and mental health correlates and risk factors for intimate partner violence among HIV-positive women in an inner-city HIV clinic.

    Illangasekare, Samantha / Tello, Monique / Hutton, Heidi / Moore, Richard / Anderson, Jean / Baron, Jillian / Chander, Geetanjali

    Women's health issues : official publication of the Jacobs Institute of Women's Health

    2012  Volume 22, Issue 6, Page(s) e563–9

    Abstract: Background: Intimate partner violence (IPV) is a serious health concern for women in the United States, and HIV-positive women experience more frequent and severe abuse compared with HIV-negative women. The goals of this study were to determine the ... ...

    Abstract Background: Intimate partner violence (IPV) is a serious health concern for women in the United States, and HIV-positive women experience more frequent and severe abuse compared with HIV-negative women. The goals of this study were to determine the prevalence of IPV among HIV-infected women receiving care in an urban clinic and to determine the HIV clinical and mental health correlates of IPV among HIV-positive women.
    Methods: We conducted a cross-sectional survey among 196 women visiting an inner-city HIV clinic. Women were eligible if they were 18 years of age or older, English speaking, and received both HIV primary and gynecologic care at the clinic. The survey queried demographics, drug and alcohol history, depressive symptoms, and IPV, using the Partner Violence Scale. Antiretroviral therapy (ART), CD4 cell count, HIV-1 RNA level, and appointment adherence were abstracted from clinical records.
    Findings: Overall, 26.5% of women reported experiencing IPV in the past year. There were no differences in sociodemographics, substance use, ART prescription, CD4 count, or HIV-1 RNA level between women who experienced IPV and those who had not. Women with mild and severe depressive symptoms were significantly more likely to report IPV compared with those without, with adjusted odds ratios of 3.4 and 5.5, respectively. Women who missed gynecologic appointments were 1.9 times more likely to report experiencing IPV.
    Conclusions: IPV is prevalent among women presenting for HIV care, and depressive symptoms or missed gynecologic appointments should prompt further screening for IPV.
    MeSH term(s) Adult ; Anti-Retroviral Agents/therapeutic use ; Attitude to Health ; Baltimore/epidemiology ; CD4 Lymphocyte Count ; Cross-Sectional Studies ; Depression/epidemiology ; Depression/etiology ; Domestic Violence/psychology ; Domestic Violence/statistics & numerical data ; Female ; HIV Infections/drug therapy ; HIV Infections/epidemiology ; HIV-1 ; Humans ; Interviews as Topic ; Logistic Models ; Male ; Mental Health ; Middle Aged ; Multivariate Analysis ; Prevalence ; Risk Factors ; Sexual Partners ; Socioeconomic Factors ; Surveys and Questionnaires ; Urban Population/statistics & numerical data ; Young Adult
    Chemical Substances Anti-Retroviral Agents
    Language English
    Publishing date 2012-08-30
    Publishing country United States
    Document type Journal Article
    ZDB-ID 1085396-0
    ISSN 1878-4321 ; 1049-3867
    ISSN (online) 1878-4321
    ISSN 1049-3867
    DOI 10.1016/j.whi.2012.07.007
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 3298: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (2.OG)
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  4. Article ; Online: A randomized controlled study of convalescent plasma for individuals hospitalized with COVID-19 pneumonia.

    Bar, Katharine J / Shaw, Pamela A / Choi, Grace H / Aqui, Nicole / Fesnak, Andrew / Yang, Jasper B / Soto-Calderon, Haideliza / Grajales, Lizette / Starr, Julie / Andronov, Michelle / Mastellone, Miranda / Amonu, Chigozie / Feret, Geoff / DeMarshall, Maureen / Buchanan, Marie / Caturla, Maria / Gordon, James / Wanicur, Alan / Monroy, M Alexandra /
    Mampe, Felicity / Lindemuth, Emily / Gouma, Sigrid / Mullin, Anne M / Barilla, Holly / Pronina, Anastasiya / Irwin, Leah / Thomas, Raeann / Eichinger, Risa A / Demuth, Faye / Luning Prak, Eline T / Pascual, Jose L / Short, William R / Elovitz, Michal A / Baron, Jillian / Meyer, Nuala J / Degnan, Kathleen O / Frank, Ian / Hensley, Scott E / Siegel, Donald L / Tebas, Pablo

    The Journal of clinical investigation

    2021  Volume 131, Issue 24

    Abstract: BackgroundAntibody-based strategies for COVID-19 have shown promise in prevention and treatment of early disease. COVID-19 convalescent plasma (CCP) has been widely used but results from randomized trials supporting its benefit in hospitalized patients ... ...

    Abstract BackgroundAntibody-based strategies for COVID-19 have shown promise in prevention and treatment of early disease. COVID-19 convalescent plasma (CCP) has been widely used but results from randomized trials supporting its benefit in hospitalized patients with pneumonia are limited. Here, we assess the efficacy of CCP in severely ill, hospitalized adults with COVID-19 pneumonia.MethodsWe performed a randomized control trial (PennCCP2), with 80 adults hospitalized with COVID-19 pneumonia, comparing up to 2 units of locally sourced CCP plus standard care versus standard care alone. The primary efficacy endpoint was comparison of a clinical severity score. Key secondary outcomes include 14- and 28-day mortality, 14- and 28-day maximum 8-point WHO ordinal score (WHO8) score, duration of supplemental oxygenation or mechanical ventilation, respiratory SARS-CoV-2 RNA, and anti-SARS-CoV-2 antibodies.ResultsEighty hospitalized adults with confirmed COVID-19 pneumonia were enrolled at median day 6 of symptoms and day 1 of hospitalization; 60% were anti-SARS-CoV-2 antibody seronegative. Participants had a median of 3 comorbidities, including risk factors for severe COVID-19 and immunosuppression. CCP treatment was safe and conferred significant benefit by clinical severity score (median [MED] and interquartile range [IQR] 10 [5.5-30] vs. 7 [2.75-12.25], P = 0.037) and 28-day mortality (n = 10, 26% vs. n = 2, 5%; P = 0.013). All other prespecified outcome measures showed weak evidence toward benefit of CCP.ConclusionTwo units of locally sourced CCP administered early in hospitalization to majority seronegative participants conferred a significant benefit in clinical severity score and 28-day mortality. Results suggest CCP may benefit select populations, especially those with comorbidities who are treated early.Trial RegistrationClinicalTrials.gov NCT04397757.FundingUniversity of Pennsylvania.
    MeSH term(s) Adult ; Aged ; Antibodies, Viral ; COVID-19/therapy ; Female ; Hospitalization ; Humans ; Immune Tolerance ; Immunization, Passive/methods ; Immunosuppression Therapy ; Incidence ; Male ; Middle Aged ; Oxygen/therapeutic use ; Pneumonia, Viral/therapy ; RNA, Viral ; Respiration, Artificial ; Risk Factors ; SARS-CoV-2 ; Treatment Outcome ; COVID-19 Serotherapy
    Chemical Substances Antibodies, Viral ; RNA, Viral ; Oxygen (S88TT14065)
    Language English
    Publishing date 2021-11-17
    Publishing country United States
    Document type Journal Article ; Randomized Controlled Trial
    ZDB-ID 3067-3
    ISSN 1558-8238 ; 0021-9738
    ISSN (online) 1558-8238
    ISSN 0021-9738
    DOI 10.1172/JCI155114
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Ua VI Zs.184: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

To top